Tricyclic compounds as Cyp1 inhibitors
US11396516B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2018 |
| Grant date | Jul 26, 2022 |
| Priority date | — |
| Expiry date | Nov 3, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides tricyclic compounds useful, e.g., in treating or preventing cardiotoxicity and cardiomyopathy in patients undergoing cardiotoxic chemotherapy. Methods of making and using the tricyclic compounds to treat cancer are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.